Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018.
immunization
live vaccinations
measles-mumps-rubella vaccine
solid organ transplant
varicella-zoster vaccine
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
11
04
2019
revised:
12
07
2019
accepted:
26
07
2019
pubmed:
10
9
2019
medline:
26
8
2020
entrez:
10
9
2019
Statut:
ppublish
Résumé
Growing evidence suggests receipt of live-attenuated viral vaccines after solid organ transplant (SOT) has occurred and is safe and needed due to lapses in herd immunity. A 2-day consortium of experts in infectious diseases, transplantation, vaccinology, and immunology was held with the objective to review evidence and create expert recommendations for clinicians when considering live viral vaccines post-SOT. For consideration of VV and MMR post-transplant, evidence exists only for kidney and liver transplant recipients. For MMR vaccine post-SOT, consider vaccination during outbreak or travel to endemic risk areas. Patients who have received antiproliferative agents (eg. mycophenolate mofetil), T cell-depleting agents, or rituximab; or have persistently elevated EBV viral loads, or are in a state of functional tolerance, should be vaccinated with caution and have a more in-depth evaluation to define benefit of vaccination and net state of immune suppression prior to considering vaccination. MMR and/or VV (not combined MMRV) is considered to be safe in patients who are clinically well, are greater than 1 year after liver or kidney transplant and 2 months after acute rejection episode, can be closely monitored, and meet specific criteria of "low-level" immune suppression as defined in the document.
Substances chimiques
Vaccines, Attenuated
0
Types de publication
Consensus Development Conference
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13571Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Chong P, Avery RK. Comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clin Ther. 2017;39(8):1581-1598.
European Centre for Disease Prevention and Control. Week 20, 13-19 May 2018. https://ecdc.europa.eu/sites/portal/files/documents/ECDC-CDTR-18-May-2018.pdf. Accessed September 19, 2018.
Center for Disease Control and Prevention. Measles Cases and Outbreaks. https://www.cdc.gov/measles/cases-outbreaks.html. Accessed September 19, 2018.
Lopez AS, Leung J, Marin M. Varicella outbreak surveillance in the United States, 2015-2016. Open Forum Infect Dis. 2017;4(suppl_1):S461-S461.
Patel M, Lee AD, Redd SB, et al. Increase in measles cases - United States, January 1-April 26, 2019. MMWR Morb Mortal Wkly Rep. 2019;68:402-404.
World Health Organization. Global Measles and Rubella Monthly Update. https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_monthlydata/en/. Accessed June 19, 2019.
Liu Y, Sun LY, Zhu ZJ, Lin W, Qu W, Zeng ZG. Measles virus infection in pediatric liver transplantation recipients. Transplant Proc. 2015;47:2715-2718.
Turner A, Jeyaratnam D, Haworth F, et al. Measles-associated encephalopathy in children with renal transplants. Am J Transplant. 2006;6:1459-1465.
Pandya A, Wasfy S, Herbert D, Allen UD. Varicella-zoster infection in pediatric solid-organ transplant recipients: a hospital-based study in the pre-varicella vaccine era. Pediatr Transplant. 2001;5:153-159.
Pacini-Edelstein SJ, Mehra M, Ament ME, Vargas JH, Martin MG, McDiarmid SV. Varicella in pediatric liver transplant patients: a retrospective analysis of treatment and outcome. J Pediatr Gastroenterol Nutr. 2003;37:183-186.
Pergam SA, Limaye AP. Varicella zoster virus (VZV) in solid organ transplant recipients. Am J Transplant. 2009;9(4):S108-S115.
Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA. 1992;267:1237-1241.
Sternfeld T, Spöri-Byrtus V, Riediger C, et al. Acute measles infection triggering an episode of liver transplant rejection. Int J Infect Dis. 2010;14:e528-530.
Arakawa Y, Matsui A, Sasaki N, Nakayama T. Agranulocytosis and thrombocytopenic purpura following measles infection in a living-related orthotopic liver transplantation recipient. Acta Paediatr Jpn. 1997;39:226-229.
Kaul A, Sharma RK, Bhadhuria D, Gupta A, Prasad N. Chickenpox infection after renal transplantation. Clin Kidney J. 2012;5(3):203-206.
Yamada N, Sanada Y, Okada N, et al. Successful rescue of disseminated varicella infection with multiple organ failure in a pediatric living donor liver transplant recipient: a case report and literature review. Virol J. 2015;12:91.
Chavers BM, Gillingham KJ, Matas AJ. Complications by age in primary pediatric renal transplant recipients. Pediatr Nephrol. 1997;11(4):399-403.
Red Book 2018-2021 Report of the Committee on Infectious Diseases. 31st ed. American Academy of Pediatrics. 2018;869-883. Section 3.
Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html. Accessed September 19, 2018.
Advisory Committee on Immunization Practices. Center for Disease Control and Prevention. https://www.cdc.gov/vaccines/hcp/acip-recs/index.html. Accessed September 19, 2018.
World Health Organization. Recommended Routine Immunization (updated: August 2018). http://www.who.int/immunization/policy/Immunization_routine_table1.pdf?ua=1. Accessed September 19, 2018.
L'Huillier AG, Green M, Danziger-Isakov L, et al. Infections among pediatric transplant candidates: an approach to decision-making. Pediatr Transplant. 2019;23:e13375.
Posfay-Barbe KM, Pittet LF, Sottas C, et al. Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am J Transplant. 2012;12:2974-2985.
Kawano Y, Suzuki M, Kawada J-I, et al. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients. Vaccine. 2015;33:1440-1445.
Shinjoh M, Miyairi I, Hoshino K, Takahashi T, Nakayama T. Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine. 2008;26:6859-6863.
Shinjoh M, Hoshino K, Takahashi T, Nakayama T. Updated data on effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine. 2015;33:701-707.
Pittet LF, Verolet CM, McLin VA, et al. Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation. Am J Transplant. 2019;19(3):844-854.
Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant. 2006;6:565-568.
Dansereau AM, Robinson JL. Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs. World J Pediatr. 2008;4(4):254-258.
Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, Bühler S. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - a systematic review of randomized trials, observational studies and case reports. Vaccine. 2017;35:1216-1226.
Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol. 1994;8:190-192.
Levitsky J, Te HS, Faust TW, Cohen SM. Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant. 2002;2:880-882.
Chaves TdSS, Lopes MH, de Souza V, et al. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant. 2005;9:192-196.
Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol. 2006;142:943-945.
Ortiz-Brizuela E, Leal-Vega F, Cuellar-Rodríguez J, Bobadilla-del-Valle M, Ponce-de-León A. Vaccine-derived varicella zoster infection in a kidney transplant recipient after zoster vaccine live administration. Vaccine. 2019;37:3576-3579.
Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr. 1993;123:87-89.
Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant. 2006;10: :78-82.
Lochlainn LN, de Gier B, van der Maas N, et al. Measles Vaccination Below 9 Months of Age: Systematic Literature Review and Meta-Analyses of Effects and Safety. The Netherlands: Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) Bilthoven; 2015.
Gans HA, Yasukawa LL, Sung P, et al. Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis. 2013;207(4):574-582.
Griffen DE. The immune response in measles: virus control, clearance and protective immunity. Viruses. 2016;8(10):282.
Centers for Disease Control and Prevention. In HamborskyJ, KrogerA, WolfeS, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington D.C.:Public Health Foundation; 2015.
Kesson AM, Grimwood K, Burgess MA, et al. Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy. J Paediatr Child Health. 1996;32(3):211-217.
Weimer R, Staak A, Susal C, et al. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int. 2005;18(2):226-236.
Weimer R, Ettrich M, Renner M. Long-term immunological effects of ATG induction - 5 year results of a prospective renal transplant study. Hum Immunol. 2014;75(6):561-569.
Weimer R, Ettrich M, Renner F, et al. ATG induction in renal transplant recipients: Long-term hazard of severe infection is associated with long-term functional T cell impairment but not the ATG-induced CD4 cell decline. Hum Immunol. 2014;75(6):561-569.
De Mercanti S, Rolla S, Cucci A, et al. Alemtuzumab long-term immunologic effect. Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm. 2016;3(1):e194.
Grenda R. Biologics in renal transplantation. Pediatr Nephrol. 2015;30(7):1087-1098.
Fishman JA. Infections in organ transplantation. Am J Transplant. 2017;17(4):856-879.
Kerkar N, Lakhole A. Pediatric liver transplantation: a North American perspective. Expert Rev Gastroenterol Hepatol. 2016;10(8):949-959.
Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation. 2005;15(80):S181-S190.
Ritter ML, Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis. 2009;11(4):290-297.
Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int. 2006;19(8):621-628.
Rituxan. Product Monograph. Hoffmann-La Roche Limited. October 13, 2016. http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Rituxan/RituxanIV_PM_E.pdf. Accessed September 19, 2018.
Nazi I, Kelton JG, Larche M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946-1953.
Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937-941.
Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010;149:3-13.
Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant. 2009;13:319-323.
Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant. 2008;8:442-445.
Haider G, Singh N. Viral infections in solid organ transplant recipients: novel updates and review of the classics. Curr Opin Infect Dis. 2017;30:579-588.
Gotoh K, Ito Y, Ohta R, et al. Immunologic and virologic analyses in pediatric liver transplant recipients with chronic high Epstein-Barr virus loads. JID. 2010;202(3):461-469.
Roosen J, Oosterlinck W, Meyns B. Routine thymectomy in congenital cardiac surgery changes adaptive immunity without clinical relevance. Interact Cardiovasc Thorac Surg. 2015;20(1):101-106.
Orland G, Shay S, Wood K. Operational tolerance after liver transplantation. J Hepatol. 2009;50:1247-1257.
Lopez AS, Zhang J, Marin M. Epidemiology of varicella during the 2-dose varicella vaccination program - United States, 2005-2014. MMWR Morb Mortal Wkly Rep. 2016;65(34):902.
Public Health Agency of Canada. https://www.canada.ca/en/public-health/services/immunization/vaccine-preventable-diseases/varicella-chickenpox.html. Accessed September 19, 2018.
Bialek SR, Perella D, Zhang J, et al. Impact of a routine two-dose varicella vaccination program on varicella epidemiology. Pediatrics. 2013;132(5):e1134-e1140.
Seward JF, Marin M. April 2, 2014. World Health Organization SAGE Working Group. http://www.who.int/immunization/sage/meetings/2014/april/2_SAGE_April_VZV_Seward_Varicella.pdf. Accessed September 19, 2018.
AidsInfo. U.S. Department of Health and Human Services. https://aidsinfo.nih.gov/guidelines/html/5/pediatric-opportunistic-infection/431/figure-1--recommended-immunization-schedule-for-hiv-infected-children-aged-0-6-years---united-states--2013. Accessed September 19, 2018.
Al-Sukaiti N, Reid B, Lavi S, et al. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome. JACI. 2010;126(4):868-869.
Moylett EH, Wasan AN, Noroski LM, Shearer WT. Live viral vaccines in patients with partial DiGeorge syndrome- clinical experience and cellular immunity. Clin Immunol. 2004;112:106-112.
Perez EE, Bokszczanin A, McDonald-McGinn D, Zacaki EH, Sullivan KE. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Paediatrics. 2003;112(4):e325-e327.
Waters V, Peters KS, La Russa P. Live viral vaccines in a DiGeorge syndrome patient. Arch Dis Child. 2007;92:519-520.
Vaccine Adverse Event Reporting System (VAERS). Centre for Disease Control and Prevention. https://vaers.hhs.gov. Accessed September 19, 2018.
Top KA, Billard MN, Gariepy MC. Canadian Immunization Research Network's (CIRN) Special Immunization Clinics Network investigators. Immunizing patients with adverse events following immunization and potential contraindications to immunization: a report from the Special Immunization Clinics Network. Pediatr Infect Dis J. 2016;35(12):e384-e391.
Canadian Adverse Events Following Immunization Surveillance System. (CAEFISS). Public Health Agency of Canada. https://www.canada.ca/en/public-health/services/immunization/canadian-adverse-events-following-immunization-surveillance-system-caefiss.html. Accessed September 19, 2018.
Canadian Immunization Monitoring Program, Active. Canadian Pediatric Society. https://www.cps.ca/en/impact. Accessed September 19, 2018.
Canadian National Vaccine Safety Network (CANVAS). Canadian Immunization Research Network. http://cirnetwork.ca/network/national-ambulatory-network/. Accessed September 19, 2018.
Vaccine Safety Datalink. Centre for Disease Control and Prevention. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html. Accessed September 19, 2018.
Bettinger JA, Rouleau I, Gariépy MC, et al. On behalf of the Public Health Agency of Canada/Canadian Institutes for Health Research Influenza Research Network. Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012. Euro Surveill. 2015;20(29). http://www.eurosurveillance.org/. pii 21189
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-100.
Danziger-Isakov L, Kumar D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the american society of transplantation infectious diseases community of practice. Clin Transplant. 2019;19:e13563.
Australian Immunisation Handbook. Vaccination for people who are immunocompromised. https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-people-who-are-immunocompromised#solid-organ-transplant-recipient. Accessed May 31, 2019.